Abstract
Objective: There is a renewed interest in the delivery of estradiol (E2) for the reduction of menopausal symptoms in young symptomatic menopausal women. This paper compares experimentally and theoretically obtained E2 plasma values by oral and transdermal delivery and compares them with relevant menopausal symptoms.
Study design: Two independent previously published studies were compared, which each contained 42 young symptomatic menopausal women. Experimentally obtained plasma values at days 1, 7 and 21 were compared with a theoretical model, taken from the literature, for describing plasma values for an oral immediate release formulation, consecutively for 21 days. Menopausal symptoms were determined in the steady state for oral and transdermal delivery with the Kuppermann index, previously not reported. In the case of oral delivery, estradiol was compared with estradiol valerate.
Results: Previously published results for transdermal delivery of E2 showed that the matrix system establishes a steady state condition with the application of the first patch. Excellent agreement between theoretically predicted and experimentally obtained E2 plasma values for oral delivery in menopausal women was obtained. Circadian E2 plasma levels were observed continuously for transdermal delivery, were seen in oral delivery during first application and disappeared when steady state was achieved. Application of the prodrug E2-valerate delayed the maximum plasma peak from 1 pm to 4 pm, similar to the transdermal matrix patch. Investigating menopausal symptoms determined with the Kuppermann index did not reveal differences between oral or transdermal “E2 kinetic (hot flushes) relationship”. This relationship was similar to symptomatic women suffering from hot flushes in untreated menopausal women or premenopausal women. Different menopausal symptoms required different E2 plasma levels: the average E2 levels higher than 23 pg/mL in plasma did abolish insomnia in 50% of postmenopausal women, with 28 pg/mL is needed to suppress 50% of dysthymia; however, rather high levels of 41 pg/mL are needed to suppress 50% of hot flushes, suggesting a rather complex mechanism beyond an E2 receptor mediated process.
Conclusion: There is a difference in the steady state between oral and transdermal E2 delivery. Steady state condition is achieved in the first application of a matrix patch, whereas with the application of a tablet the steady state is achieved in transdermal delivery within 12–14 days. Our reported calculated missed intake of a E2 tablet shows that E2 plasma levels drop for 4 days consecutively. Our conducted study has several limitations: firstly, no cross-over was conducted, but a rather cumbersome mathematical modeling; secondly, healthy women with no accompanying severe diseases were included in this study. The higher the oral dose, the higher the E2 steady state levels, but the time to achieve steady state levels is independent from the E2 dose.
Acknowledgement
One of the authors (UDR) wishes to express his respect to Prof. Emeritus. Dr. Norman Ho from the University of Michigan. He developed the method of “PHYSICAL MODEL APPROACH” to compare a defined situation with a new “undefined” situation and determine similarities and differences. His method is of tremendous importance for medicine.
References
1. Pines A. Halleluiah, lessons from the WHI by WHI people. Climacteric 2013;16:536–8.10.3109/13697137.2013.766406Search in Google Scholar PubMed
2. Lobo RA. Where are we 10 years after the women′s health initiative? J Clin Endocrinol Metab 2013;98:1771–80.10.1210/jc.2012-4070Search in Google Scholar PubMed
3. Rohr UD, Saeger-Lorenz K. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: theoretical predictions with an oscillating diffusion coefficient model. J Pharm Sci 2002;91:822–44.10.1002/jps.10138Search in Google Scholar PubMed
4. Rohr UD, Saeger-Lorenz K. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: experimental results. J Pharm Sci 2002;91:810–21.10.1002/jps.10137Search in Google Scholar PubMed
5. Fields R, Fisher E, Kramer S, Kwan E, Wong A. An analysis of the ortho evra birth control patch. Library of The Cornell University, 2006. http://ecommons.cornell.edu/handle/1813/3058.Search in Google Scholar
6. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002;346:340–52.10.1056/NEJMra000471Search in Google Scholar PubMed
7. Lévy F, Gheusi G, Keller M. Plasticity of the parental brain: a case for neurogenesis. J Neuroendocrinol 2011;23:984–93.10.1111/j.1365-2826.2011.02203.xSearch in Google Scholar PubMed
8. Huang C, Gu H, Wang Y, Wang M. Estrogen-induced SDF-1 production is mediated by estrogen receptor-α in female hearts after acute ischemia and reperfusion. Surgery 2011;150:197–203.10.1016/j.surg.2011.05.010Search in Google Scholar PubMed PubMed Central
9. Jasen P. Menopause and historical constructions of cancer risk. Can Bull Med Hist 2011;28:43–70.10.3138/cbmh.28.1.43Search in Google Scholar PubMed
10. Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561–82.Search in Google Scholar
11. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. Arzneimittelforschung 1996;46:766–73.Search in Google Scholar
12. Wiegratz I, Fink T, Rohr UD, Lang E, Leukel P, Kuhl H. Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol. Zentralbl Gynakol 2001;123:505–12.10.1055/s-2001-18223Search in Google Scholar PubMed
13. Smith JM, Van Ness HC. Introduction to chemical engineering thermodynamics, 2nd ed. Columbus, OH: McGraw-Hill, 1959:34.Search in Google Scholar
14. Pietruszko R, Ringold HJ, Li TK, Vallee BL, Åkeson Å, Theorell H. Structure and function relationships in isoenzymes of horse liver alcohol dehydrogenase. Nature 1996;221:440–3.10.1038/221440a0Search in Google Scholar PubMed
15. Dhillon S, Gill K. Basic pharmacokinetics. In: Dhillon S, Kostrzewski E, editors. Clinical pharmacokinetics. London: Pharmaceutical Press, 2006:1–44.Search in Google Scholar
16. Srouji SS, Pagán YL, D′Amato F, Dabela A, Jimenez Y, Supko JG, Hall JE. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. Clin Endocrinol Metab 2007;92:1347–52.10.1210/jc.2006-2716Search in Google Scholar PubMed
17. Su J, Sun P, Li X, Alan H. Fitting compartmental models to multiple dose pharmacokinetic data. Paper SP11-2009. Merck Co.Search in Google Scholar
18. Davidian M, Giltinan D. Nonlinear models for repeated measurement data. New York: Chapman and Hall, 1995.Search in Google Scholar
19. Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol 2012;7:1583–93.10.1097/JTO.0b013e31826146eeSearch in Google Scholar PubMed PubMed Central
20. Akhter KP, Ahmad M. Estimation of area under the plasma concentration time curve using a combination of numerical methods. J Pure Appl Sci 2002;21:63–77.Search in Google Scholar
21. Akaike H. An information criterion. Math Sci 1976;14:5–9.Search in Google Scholar
22. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The menopause rating scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric 2000;3:50–8.10.3109/13697130009167599Search in Google Scholar PubMed
23. Jurkovic D, Ross D, Aslam N, Whitehead M. Diurnal variation in uterine artery blood flow in post-menopausal women on oestrogen hormone replacement therapy. Hum Reprod 1999;14:2716–9.10.1093/humrep/14.11.2716Search in Google Scholar PubMed
24. Shechter A, Varin F, Boivin DB. Circadian variation of sleep during the follicular and luteal phases of the menstrual cycle. Sleep 2010;33:647–56.10.1093/sleep/33.5.647Search in Google Scholar PubMed PubMed Central
25. Albertsson-Wikland K, Rosberg S, Lannering B, Dunkel L, Selstam G, Norjavaara E. Twenty-four-hour profiles of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol levels: a semilongitudinal study throughout puberty in healthy boys. J Clin Endocrinol Metab 1997;82:541–9.Search in Google Scholar
26. Steingold KA, Laufer L, Chetkowski RJ, DeFazio JD, Matt DW, Meldrum DR, Judd HL. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1987;65:773–8.10.1210/jcem-65-4-773Search in Google Scholar PubMed
27. LaCroix A, Chlebowski R, Manson J. Health outcomes after stopping conjugated equine estrogen among postmenopausal women with prior hysterectomy: a randomized controlled tria. J Am Med Assoc 2011;305:1305–14.10.1001/jama.2011.382Search in Google Scholar PubMed PubMed Central
28. Jalava-Broman J, Mäkinen J, Ojanlatva A, Jokinen K, Sillanmäki L, Rautava P. Change in the frequency of HRT use from 2000 to 2005 and reasons to discontinue: follow-up of a normal cohort in Finland. Acta Obstet Gynecol Scand 2011;90:351–7.10.1111/j.1600-0412.2011.01069.xSearch in Google Scholar PubMed
29. Oliveira DS, Hachul H, Goto V, Tufik S, Bittencourt LR. Effect of therapeutic massage on insomnia and climacteric symptoms in postmenopausal women. Climacteric 2012;15:21–9.10.3109/13697137.2011.587557Search in Google Scholar PubMed
30. Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011;18:1052–9.10.1097/gme.0b013e3182175e5cSearch in Google Scholar PubMed
31. Wang X, He H, Leng W, Tang X. Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method. Int J Pharm 2006;317:40–6.10.1016/j.ijpharm.2006.02.055Search in Google Scholar
32. Egras AM, UmLand EM. The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms. Int J Gen Med 2010;3:147–51.Search in Google Scholar
33. Sajtos B, Herold J, Winkler UH, Schindler AE. Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch. Zentralbl Gynakol 1995;117:524–30.Search in Google Scholar
34. Merz CN, Olson MB, McClure C, Yang YC, Symons J, Sopko G, Kelsey SF, Handberg E, Johnson BD, Cooper-DeHoff RM, Sharaf B, Rogers WJ, Pepine CJ. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J 2010;159:987–97.10.1016/j.ahj.2010.03.024Search in Google Scholar
35. Kräuchi K, Cajochen C, Werth E, Wirz-Justice A. Functional link between distal vasodilation and sleep-onset latency? Am J Physiol Regul Integr Comp Physiol 2000;278:R741–8.10.1152/ajpregu.2000.278.3.R741Search in Google Scholar
36. Lønning PE, Dowsett MS, Jacobs S, Schem B, Hardy J, Powles TJ. There are no circadian estradiol plasma profiles in postmenopausal women. J Steroid Biochem 1989;43:551–3.10.1016/0022-4731(89)90143-XSearch in Google Scholar
37. Goji K. 24-hour plasma profile of estradiol and testosterone in pubital girls. J Clin Endocrinol Metab 1974;38:1629–35.Search in Google Scholar
38. Gangar KF, Vyas S, Whitehead M, Crock D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal estradiol and time in menopause. Lancet 1991;338:839–42.10.1016/0140-6736(91)91500-TSearch in Google Scholar
39. Honnebier MB. Circadian timekeeping during pregnancy. Endocrinology 1992;131:2051–8.10.1210/endo.131.5.1330486Search in Google Scholar PubMed
40. Okatani Y, Sagara Y. Amplification of nocturnal melatonin secretion in women with functional secondary amenorrhoea: relation to endogenous oestrogen concentration. Clin Endocrinol (Oxf) 1994;41:763–70.10.1111/j.1365-2265.1994.tb02791.xSearch in Google Scholar PubMed
41. Okatani Y, Sagara Y. Enhanced nocturnal melatonin secretion in women with functional secondary amenorrhea: relationship to opioid system and endogenous estrogen levels. Horm Res 1995;43:194–9.10.1159/000184277Search in Google Scholar PubMed
42. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999;13:857–68.10.1096/fasebj.13.8.857Search in Google Scholar PubMed
43. Davis S, Mirick DK. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control 2006;17:539–45.10.1007/s10552-005-9010-9Search in Google Scholar PubMed
44. Yon de Jonage-Canonico MB, Lenoir V, Scholler R, Kerdelhué B. Long-term dysregulation of circadian and 17-beta estradiol-induced LH, prolactin and corticosterone secretion after dimethylbenz (a) anthracene administration in the Sprague-Dawley female rat. Breast Cancer Res Treat 2005;92:47–50.10.1007/s10549-005-0270-6Search in Google Scholar PubMed
45. Bollinger T, Bollinger A, Naujoks J, Lange T, Solbach W. The influence of regulatory T cells and diurnal hormone rhythms on T helper cell activity. Immunology 2010;131:488–500.10.1111/j.1365-2567.2010.03320.xSearch in Google Scholar PubMed PubMed Central
46. Cutolo M, Sulli A, Pizzorni C, Secchi ME, Soldano S, Seriolo B, Straub RH, Otsa K, Maestroni GJ. Circadian rhythms: glucocorticoids and arthritis. Ann N Y Acad Sci 2006;1069:289–99.10.1196/annals.1351.027Search in Google Scholar PubMed
47. Holzheimer RG, Curley P, Saporoschetz IB, Doherty JM, Mannick JA, Rodrick ML. Circadian rhythm of cytokine secretion following thermal injury in mice: implications for burn and trauma research. Shock 2002;17:527–9.10.1097/00024382-200206000-00015Search in Google Scholar PubMed
48. Schindler AE. Transdermal and oral hormone substitution with estrogens: a comparison. Zentralbl Gynakol 1995;117:504–7.Search in Google Scholar
49. Perrone G, Capri O, Galoppi P, Patacchioli FR, Bevilacqua E, de Stefano MG, Brunelli R. Menopausal symptoms after the discontinuation of long-term hormone replacement therapy in women under 60: a 3-year follow-up. Gynecol Obstet Invest 2013;76:38–43.10.1159/000351104Search in Google Scholar PubMed
50. Morton TL, Gattermeir DJ, Petersen CA, Day WW, Schumacher RJ. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women. J Clin Pharmacol 2009;49:1037.10.1177/0091270009339187Search in Google Scholar PubMed
51. Formby B, Schmidt F. Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study. Int J Gen Med 2011;4:159–63.10.2147/IJGM.S16139Search in Google Scholar PubMed PubMed Central
52. Chen Y, Zeleniuch-Jacquotte A, Arslan AA, Wojcik O, Toniolo P, Shore RE, Levitz M, Koenig KL. Endogenous hormones and coronary heart disease in postmenopausal women. Atherosclerosis 2011;216:414–9.10.1016/j.atherosclerosis.2011.01.053Search in Google Scholar PubMed PubMed Central
53. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 2007;14:978–84.10.1097/gme.0b013e318054e2e7Search in Google Scholar PubMed
54. Mitchell ES, Woods NF. Cognitive symptoms during the menopausal transition and early postmenopause. Climacteric 2011;14:252–61.10.3109/13697137.2010.516848Search in Google Scholar PubMed
55. Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause 2011;18: 611–20.10.1097/gme.0b013e318204a05cSearch in Google Scholar
56. Woods NF, Mitchell ES. Symptom interference with work and relationships during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women′s Health Study. Menopause 2011;18:654–61.10.1097/gme.0b013e318205bd76Search in Google Scholar
57. Mann E, Smith M, Hellier J, Hunter MS. A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol. BMC Cancer 2011;11:44.10.1186/1471-2407-11-44Search in Google Scholar
58. Elkins G, Fisher W, Johnson A. Mind-body therapies in integrative oncology. Curr Treat Options Oncol 2010;11:128–40.10.1007/s11864-010-0129-xSearch in Google Scholar
59. Cray L, Woods NF, Mitchell ES. Symptom clusters during the late menopausal transition stage: observations from the Seattle Midlife Women′s Health Study. Menopause 2010;17:972–7.10.1097/gme.0b013e3181dd1f95Search in Google Scholar
60. Bergemann N, Mundt C, Parzer P, Jannakos I, Nagl I, Salbach B, Klinga K, Runnebaum B, Resch F. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005;73:357–66.10.1016/j.schres.2004.06.013Search in Google Scholar
61. Hafner LM, Cunningham K, Beagley KW. Ovarian steroid hormones: effects on immune responses and Chlamydia trachomatis infections of the female genital tract. Mucosal Immunol 2013;6:859–75.10.1038/mi.2013.46Search in Google Scholar
62. Dada OA, Martins OO. Drug effects on the intestinal absorption of estrogens. Steroid Biochem 1983;1C:821–5.10.1016/0022-4731(83)90018-3Search in Google Scholar
63. Brewster D, Jones RS, Symons AM. Effects of neomycin on the biliary excretion and enterohepatic circulation of mestranol and 17beta-oestradiol. Biochem Pharmacol 1977;26:943–6.10.1016/0006-2952(77)90471-3Search in Google Scholar
64. Burger HG. Diagnostic role of follicle stimulating hormone (FSH) measurements during menopausal transition – an analysis of FSH, oestraiol and inhibim. Eur J Endocrinol 1994;130:38–42.10.1530/eje.0.1300038Search in Google Scholar PubMed
©2014 by De Gruyter
